SCHEDULE: Kynam Capital Discloses 1.54% Stake in Viridian Therapeutics

Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang reported beneficial ownership of 1.54% of Viridian Therapeutics, Inc. common stock.

Summary

• Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang collectively reported beneficial ownership of 1,470,541 shares of Viridian Therapeutics, Inc. common stock.
• This represents 1.54% of the total outstanding shares of Viridian Therapeutics, Inc.
• The reporting persons share both voting and dispositive power over these shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a previous filing existed.
• The securities are Common Stock with a $0.01 par value and CUSIP number 92790C104.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as Schedule 13G amendments are routine disclosures of passive ownership and do not inherently convey positive or negative sentiment about the company's operations or prospects.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future performance or outlook.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive investors holding between 5% and 20% of a company's stock, or institutional investors holding over 5%. This amendment indicates Kynam Capital Management's continued or adjusted passive stake in Viridian Therapeutics, a common occurrence in the biotech sector where institutional investment is prevalent.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, confirming a passive stake by Kynam Capital Management.

Key Dates

Keywords

Viridian Therapeutics, Kynam Capital Management, Yue Tang, Schedule 13G, Beneficial Ownership, Common Stock, VRDN, Institutional Ownership